Receive Our Newsletter

Hemophilia Bleeding Disorder Industry News
Industry News

Octapharma Launches Co-Pay Assistance Program

Octapharma USA announced on January 27, 2015 information about a new financial support program for the bleeding disorders community. The Octapharma Co- Pay Assistance Program is available to von Willebrand’s Disease (VWD) patients who are currently receiving wilate® [von Willebrand Factor/Coagulation Factor VIII Complex (Human)] or have a prescription to begin therapy. The new program offers […]

Industry News

FDA To Review CSL Behring’s New Long-Lasting Hemophilia B Product

CSL Behring announced that the U.S. Food and Drug Administration (FDA) has accepted for review its Biologics License Application (BLA) for the marketing authorization of its long-acting fusion protein linking recombinant coagulation factor IX with recombinant albumin (rIX-FP). Upon FDA approval, rIX-FP will provide hemophilia B patients with a long-acting treatment option with dosing intervals up […]

Industry News

FDA Accepts CSL Behring’s Application for New Long-Acting Hemophilia B Product

This is an edited version of a press release from CSL Behring. To read the full release, please click here. ____________________  CSL Behring announced that the U.S. Food and Drug Administration (FDA) has accepted for review its Biologics License Application (BLA) for the marketing authorization of its long-acting fusion protein linking recombinant coagulation factor IX with recombinant […]

Industry News

Biogen Idec Forms Partnership to Focus on Gene Therapy for Hemophilia

Biogen Idec, Fondazione Telethon, and Ospedale San Raffaele have entered into a worldwide collaboration to jointly develop gene therapies for the treatment of both hemophilia A and B. The agreement will combine San Raffaele – Telethon Institute for Gene Therapy’s (TIGET) extensive expertise in creating new gene therapy strategies and developing them from the bench to bedside […]

Industry News

Bayer’s Hemophilia Leadership Application Closes 3/13

The Bayer Hemophilia Leadership Development Program was created by Bayer — with hemophilia advocacy organizations, healthcare professional thought leaders, and other community advocates — to help prepare future leaders in the hemophilia community. For years, Bayer has offered motivated, young individuals who are touched by hemophilia a paid internship at Bayer’s U.S. headquarters in New […]

industry_news_fb

Baxter Files For FDA Approval of Recombinant Treatment For von Willebrand Disease

Baxter International Inc. today announced that the company has submitted a biologics license application (BLA) to the United States (U.S.) Food and Drug Administration (FDA) for the approval of BAX111, the first highly-purified recombinant von Willebrand Factor (rVWF) in clinical development as a treatment for patients with von Willebrand disease, the most common type of […]

industry_news_fb

CSL Behring Submits FDA Approval for Long Acting Hemophilia B Product

CSL Behring announced on Tuesday, December 16, 2014 that it has submitted a biologics license application (BLA) to the United States Food and Drug Administration (FDA) for the marketing authorization of its long-acting fusion protein linking recombinant coagulation factor IX with recombinant albumin (rIX-FP). Once approved by the FDA, rIX-FP (Coagulation Factor IX {Recombinant}, Albumin […]

industry_news_fb

Pfizer Establishes Gene Therapy Partnership

Pfizer Inc. announced on Monday, December 8, 2014  two strategic decisions to expand the company’s rare disease research and development activities through the establishment of a gene therapy platform to investigate potential treatments for patients. First is an agreement with Spark Therapeutics to develop SPK-FIX, a program incorporating a bio-engineered AAV vector for the potential […]

industry_news_fb

Baxter Seeks OK to Sell New Hemophilia Drug

Baxter International submitted an application to the Food and Drug Administration for the approval of a key hemophilia drug. The drug, BAX 855, is an extended-release version of its flagship hemophilia drug Advate, which is sold in dozens of countries. The treatment is seen as a key part of the company’s drug pipeline and its […]

Industry News

CSL Behring Announces 2014 Gettin’ in the Game Winners

CSL Behring’s Gettin’ in the Game program, like our FitFactor program, encourages patients with hemophilia, von Willebrand disease (vWD), and other bleeding disorders to become active and stay active, touting the physical and mental benefits of sports and other activities. Recently, CSL Behring held their 13th Junior National Championship program, an annual golf and baseball […]

Page 13 of 27« FirstPrevious9101112131415161718NextLast »

Assisting and Advocating for the Bleeding Disorders Community